MRK · 10-Q · 2026Q3 · Full report

KEYTRUDA QLEX Adoption

Merck & Co., Inc. · 2026-11-04 · Importance 26 · Surprise 24

Keytruda Qlex is a subcutaneous pembrolizumab combination, and the filing reports U.S. and international demand growth for the combined Keytruda/Keytruda Qlex franchise. U.S. demand reflected greater utilization in earlier-stage indications, including certain breast, bladder, head and neck, and cervical cancers, as well as metastatic urothelial cancer. International growth reflected uptake in earlier-stage cervical, triple-negative breast, non-small cell lung and renal cell cancers, alongside metastatic urothelial and endometrial cancer demand. Japan approved Keyject, the subcutaneous formulation, across Keytruda-approved indications in September 2026; European availability is affected by reimbursement procedures and injunctions in several countries.